EUCTR2014-001326-15-ES进行中（未招募）1 期
A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterations
Ignyta Inc.0 个研究点目标入组 83 人开始时间: 2014年7月4日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 83
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Willing and able to provide written IRB/IEC-approved Informed Consent.
- •2. Have histologically or cytologically confirmed diagnosis of relapsed or refractory locally advanced or metastatic solid tumors that have a TrkA, TrkB, TrkC, ROS1, or ALK molecular alteration (as defined in Section 7.1) and for whom no alternative effective standard therapy is available or for whom standard therapy is considered unsuitable or intolerable.
- •For Phase 2a: Patients with locally advanced or metastatic solid tumors that have:
- •? Cohort #1: a TrkA molecular alteration.
- •? Cohort #2: a TrkB or TrkC molecular alteration.
- •? Cohort #3: a ROS1 molecular alteration.
- •? Cohort #4a: patients with locally advanced or metastatic solid tumors that have an ALK molecular alteration who are naïve to prior treatment with ALK inhibitors (patients with locally advanced or metastatic non-small cell lung cancer who have not received prior therapy with crizotinib will be excluded) or who have failed prior treatment with a single ALK inhibitor, including those who did not tolerate crizotinib. If a patient is refractory to one or more ALK inhibitors, then the patient must undergo a tumor biopsy following failure to prior therapy.
- •? Cohort #4b: patients with locally advanced or metastatic solid tumors that have an ALK molecular alteration who have failed prior treatment with more than one ALK inhibitor. If a patient is refractory to one or more ALK inhibitors, then the patient must undergo a tumor biopsy following failure to prior therapy.
- •3. Tumor tissue available for analysis. Only non-CNS lesions may be re-biopsied and must incur minimal risk to patients (e.g., percutaneous biopsy).
- •4. Measurable disease according to RECIST version 1.1.
- •5. Prior cancer therapy is allowed, including crizotinib and investigational drugs. At the time of treatment start, at least 2-4 weeks must have elapsed after prior cytotoxic chemotherapy (at least 6 weeks for nitrosureas, mitomycin C and liposomal doxorubicin). In the absence of toxicity, 7 days must have elapsed since completion of prior non-cytotoxic cancer therapy.
- •6. Prior radiotherapy is allowed if >14 days have elapsed since end of treatment, provided that no more than 25% of bone marrow reserve has been irradiated.
- •7. Patients with controlled asymptomatic CNS involvement are allowed in absence of therapy with anticonvulsants. Patients not requiring or requiring steroids at stable dose (? 4 mg/day dexamethasone or equivalent) for at least 2 weeks are eligible.
- •8. Patients who have received brain irradiation must have completed whole brain radiotherapy and gamma knife at least 4 weeks prior to enrollment.
- •9. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to NCI CTCAE (Version 4.03) Grade ? 1 or to the baseline laboratory values as defined in Inclusion Criterion Number 13.
- •10. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ? 2.
- •11. Adult patients (age ?18).
- •12. Life expectancy of at least 3 months.
- •13. Baseline laboratory values fulfilling the study requirements.
- •14. Females of child-bearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Females of childbearing potential must agree to avoid pregnancy during the study and agree upon the use of effective contraceptive methods (hormonal or barrier method of birth control, or abstinenc
排除标准
- •1. Current participation in another therapeutic clinical trial.
- •2. Known symptomatic brain metastases or leptomeningeal involvement as assessed by MRI or contrast CT scan examination. Patients with asymptomatic leptomeningeal carcinomatosis may be enrolled at the discretion of the Investigator.
- •3. History of previous cancer, except squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 3 years.
- •4. Incomplete recovery from any surgery prior to treatment.
- •5. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/ peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, symptomatic bradycardia, requirement for anti-arrhythmic medication.
- •6. History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 450 milliseconds).
- •7. History of additional risk factors for torsade de pointes (e.g., heart failure, family history of long QT syndrome).
- •8. Use of concomitant medications (refer to Section 10 of protocol) that increase or possibly increase the risk to prolong the QTc interval and/or induce torsades de pointes ventricular arrhythmia.
- •9. Known active infections (bacterial, fungal, viral including HIV positivity).
- •10. Gastrointestinal disease (e.g., Crohn?s disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
- •11. Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.
- •12. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- •13. History of stroke or seizure.
- •14. Peripheral neuropathy ? Grade 1.
研究者
相似试验
进行中（未招募）
不适用
A clinical study to investigate the safety and efficacy of RXDX-101 in patients with locally Advanced or Metastatic Cancerocally advanced or metastatic solid tumorsMedDRA version: 17.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864EUCTR2014-001326-15-GBIgnyta, Inc.160
进行中（未招募）
1 期
Study of oral FGF401 in adult patients with liver cancer or other types of cancerHepatocellular carcinoma or other solid tumors characterized by positive FGFR4 and KLB expressionMedDRA version: 17.1 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002929-35-FRovartis Pharma Services AG130
进行中（未招募）
1 期
Study of oral FGF401 in adult patients with liver cancer or other types of cancerEUCTR2014-002929-35-DEovartis Pharma Services AG240
进行中（未招募）
1 期
Study of oral FGF401 in adult patients with liver cancer or other types of cancerEUCTR2014-002929-35-ESovartis Farmacéutica, S.A.130
进行中（未招募）
不适用
An Open Labelled, Clinical Phase II Study With Oral Cis-U-Hydroxy-L-Proline (CHP) in 45 Patients With:- Chronic viral hepatitis- Chronic alcoholic liver diseases without cirrhosis- Compensated alcoholic liver cirrhosis- Primary Billiary Cirrhosis or Primary Sclerosing Cholangitis - B025-L CHP Chronic liver diseaseChronic viral hepatitis, Chronic alcoholic liver diseases without cirrhosis, Compensated alcoholic liver cirrhosis, Primary Billiary Cirrhosis or Primary Sclerosing CholangitisMedDRA version: 1.1Level: SOCClassification code 10019805EUCTR2005-001454-24-LTRIEMSER Arzneimittel AG45